Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 261.60 INR
Change Today +15.40 / 6.26%
Volume 223.8K
As of 6:24 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

claris lifesciences ltd (CLAR) Snapshot

Open
249.70
Previous Close
246.20
Day High
262.70
Day Low
248.00
52 Week High
04/13/15 - 358.00
52 Week Low
06/2/14 - 141.25
Market Cap
14.3B
Average Volume 10 Days
1.3M
EPS TTM
23.76
Shares Outstanding
54.6M
EX-Date
01/20/14
P/E TM
11.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for CLARIS LIFESCIENCES LTD (CLAR)

Related News

No related news articles were found.

claris lifesciences ltd (CLAR) Related Businessweek News

No Related Businessweek News Found

claris lifesciences ltd (CLAR) Details

Claris Lifesciences Limited, together with its subsidiaries, operates as a sterile injectables pharmaceutical company worldwide. The company manufactures and markets products for anesthesia and analgesia; blood; anti-infectives, such as quinolone, beta lactum, anti-fungal, and aminoglycoside; and oncology segments. It also provides enteral nutrition products and delivery systems; and therapy, peritoneal dialysis products, and medicines for renal and transplant. In addition, the company offers injectables for various therapeutic groups, including anti-emetics, CNS, cardiology, anti-malaria, haematinics, etc in various delivery systems, such as glass bottles, vials, ampoules, and non-PVC/PVC bags. It serves government and private hospitals, aid agencies, and nursing homes. The company was incorporated in 1994 and is headquartered in Ahmedabad, India.

Founded in 1994

claris lifesciences ltd (CLAR) Top Compensated Officers

Vice Chairman, Managing Director and Member o...
Total Annual Compensation: 15.0M
Chief Financial Officer, Whole Time Director,...
Total Annual Compensation: 4.7M
Whole Time Director
Total Annual Compensation: 4.7M
Compensation as of Fiscal Year 2013.

claris lifesciences ltd (CLAR) Key Developments

Claris Lifesciences Limited Receives Supplemental ANDA Approval for Fluconazole Injection in 50 ml PVC Bags

Claris Lifesciences Limited (Claris) announced that it has received the Supplemental Abbreviated New Drug Application (ANDA) approval for Fluconazole Injection in the United States of America (US). Claris currently marketing Fluconazole in 2 mg/ml formulation packed in 100 ml and 200 ml PVC Bags and now with the approval of supplemental ANDA, Claris is the only company to be able to sell Fluconazole in 50 ml variant in the US. By launching this variant Claris will be addressing the need of the medical fraternity.

Claris Lifesciences Limited Announces Settlement of Litigations and License Agreement for its Generic DIPRIVAN in USA

Claris Lifesciences Limited (Claris) confirms that it has reached a settlement and license agreement, ending all pending litigation with Fresenius Kabi USA Inc. with reference to the alleged infringement of a patent relating to Propofol for Injection, 10 mg/ml, which is a generic version of DIPRIVAN. Under the terms of the Settlement and License Agreement, Claris and Claris Lifesciences Inc. (USA) has been granted approval to sell its generic version of Propofol for Injection beginning 15th October 2016, prior to the 1st June 2025 expiry of the patent that formed the basis of the litigation.

Cadilla, Lupin, Cipla, Sun Pharma, Dr Reddy's, Pfizer and Sandoz Reportedly Eyes Takeover Of CLARIS Lifesciences's Injectables Business

Pfizer Limited (BSE:500680), Novartis AG (SWX:NOVN), Lupin Limited (BSE:500257), Cipla Limited (BSE:500087), Dr. Reddy's Laboratories Ltd. (BSE:500124), Sun Pharmaceutical Industries Limited (BSE:524715) and Cadila Healthcare Limited (BSE:532321) are reportedly looking to acquire the injectables business from Claris Lifesciences Limited (BSE:533288).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLAR:IN 261.60 INR +15.40

CLAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLAR.
View Industry Companies
 

Industry Analysis

CLAR

Industry Average

Valuation CLAR Industry Range
Price/Earnings 10.9x
Price/Sales 2.2x
Price/Book 1.1x
Price/Cash Flow 7.9x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLARIS LIFESCIENCES LTD, please visit www.clarislifesciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.